Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Accordion Pill Zaleplon is an oral, extended-release formulation of the nonbenzodiazepine hypnotic zaleplon, engineered using the “Accordion Pill” gastric-retentive delivery platform to prolong residence in the stomach and provide a more sustained zaleplon plasma profile compared with immediate-release capsules. Zaleplon is a pyrazolopyrimidine sedative-hypnotic that selectively modulates the gamma-aminobutyric acid type A (GABAA) receptor complex at the benzodiazepine omega-1 (BZ1) site on the alpha subunit, enhancing GABAergic inhibitory neurotransmission to promote sleep onset in patients with insomnia.[3][5] The Accordion Pill technology uses layered, expandable polymeric films that unfold in the stomach to release zaleplon gradually, with the goal of improving sleep maintenance while limiting next-morning residual effects relative to higher-dose immediate-release zaleplon.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Accordion Pill Zaleplon.